Market Overview

JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity

Share:
Related ALXN
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
Implications from Soliris patent ruling in Brazil likely immaterial says Alexion (Seeking Alpha)

In a report published Monday, JP Morgan analyst Anupam Rama upgraded the rating on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) from Not Rated to Overweight, with a price target of $249. The analyst believes that the soon-to-be-launched Strensiq and Kanuma products have peak sales capabilities of over $1 billion and over $700 million, respectively.

The analyst expects the company pipeline to diversify Alexion's commercial base in the near future, with the expected product launches of Strensiq, for the treatment of hypophosphatasia, and Kanuma, for LAL deficiency, in the near term.

"Of note, Alexion is entering a data rich 12-24 months, which is underappreciated point, in our view, with multiple proof-of-concept and pivotal trials reading out," Rama stated. More details on the products are expected at the time of the Q2 results announcement.

"The combination of continued execution of Soliris, near-term diversification of commercial product mix, intermediate-term late-stage clinical value drivers, and strong leadership, is the basis of our Overweight rating," the JP Morgan report added.

The analyst believes that Soliris could prove to have "blockbuster" potential for Myasthenia Gravis (MG) and Neuromyelitus Optica (NMO). While data on MG is expected in 2016, data on NMO trials is expected in 2017.

Latest Ratings for ALXN

DateFirmActionFromTo
Mar 2018NomuraMaintainsBuyBuy
Mar 2018Credit SuisseMaintainsOutperformOutperform
Feb 2018BMO CapitalMaintainsOutperformOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!